MIDLOTHIAN, Va., Oct. 9 /PRNewswire/ -- PARI Respiratory Equipment's breath-enhanced nebulizer, the PARI LC PLUS, and PRONEB Ultra compressor deliver Dey, L.P.'s new COPD medication, Perforomist Inhalation Solution, that launched nationwide yesterday. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE: MYL).
Perforomist (formoterol fumarate) Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Perforomist Inhalation Solution will be available through retail pharmacies, hospitals, long-term care facilities, and home healthcare companies.
"We are extremely pleased that our PARI LC PLUS nebulizer and PRONEB Ultra compressor were chosen exclusively for the clinical trials for Perforomist Inhalation Solution and are on the package insert. PARI's nebulizers and compressors are the top performers in the industry, which makes them a perfect fit for many of DEY's products -- including DuoNeb, AccuNEB, and now Perforomist," said Geoff A. Hunziker, President of PARI in the United States.
Formoterol fumarate is a rapid, long-acting beta(2)-agonist (LABA) that has been previously available in the U.S. as a dry powder formulation and has twenty years of worldwide use.
The safety and efficacy of Perforomist Inhalation Solution have been
established in clinical trials when administered using the PARI LC PLUS
nebulizer (with a facemask or mouthpiece) and the PARI PRONEB Ultra
compressor. The safety and efficacy of Perforomist Inhalation Solution
delivered from other compressor-based nebulizer combinations and
non-compressor based nebulizer systems have not been establis
|SOURCE PARI Respiratory Equipment, Inc.|
Copyright©2007 PR Newswire.
All rights reserved